Capstone Investment Advisors LLC Acquires New Shares in Privia Health Group, Inc. $PRVA

Capstone Investment Advisors LLC bought a new position in Privia Health Group, Inc. (NASDAQ:PRVA) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 31,832 shares of the company’s stock, valued at approximately $819,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Renaissance Group LLC acquired a new position in shares of Privia Health Group during the fourth quarter valued at $7,776,000. Oppenheimer Asset Management Inc. bought a new position in Privia Health Group in the second quarter valued at about $5,841,000. Principal Financial Group Inc. increased its position in Privia Health Group by 1.6% in the fourth quarter. Principal Financial Group Inc. now owns 2,787,802 shares of the company’s stock worth $66,099,000 after purchasing an additional 43,589 shares during the period. Van Berkom & Associates Inc. raised its holdings in Privia Health Group by 5.4% during the 1st quarter. Van Berkom & Associates Inc. now owns 4,053,043 shares of the company’s stock worth $83,371,000 after purchasing an additional 208,787 shares during the last quarter. Finally, Louisiana State Employees Retirement System bought a new stake in Privia Health Group during the 1st quarter worth about $1,055,000. 94.48% of the stock is currently owned by institutional investors.

Privia Health Group Trading Down 0.3%

NASDAQ:PRVA opened at $20.79 on Friday. Privia Health Group, Inc. has a 1-year low of $19.53 and a 1-year high of $28.82. The firm has a market capitalization of $2.66 billion, a price-to-earnings ratio of 99.00, a PEG ratio of 1.64 and a beta of 0.85. The business’s 50-day moving average price is $24.33 and its two-hundred day moving average price is $23.18.

Privia Health Group (NASDAQ:PRVA) last posted its earnings results on Thursday, August 6th. The company reported $0.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.07 by $0.12. The company had revenue of $632.63 million during the quarter, compared to analyst estimates of $597.33 million. Privia Health Group had a return on equity of 3.52% and a net margin of 1.19%.The company’s revenue for the quarter was up 21.4% compared to the same quarter last year. During the same period in the previous year, the company earned $0.24 EPS. Sell-side analysts predict that Privia Health Group, Inc. will post 0.27 earnings per share for the current year.

Insider Activity at Privia Health Group

In other Privia Health Group news, CFO David Mountcastle sold 24,734 shares of the company’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $27.50, for a total value of $680,185.00. Following the completion of the sale, the chief financial officer owned 186,728 shares of the company’s stock, valued at approximately $5,135,020. This represents a 11.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Matthew Shawn Morris sold 88,110 shares of the stock in a transaction on Friday, June 26th. The stock was sold at an average price of $25.33, for a total transaction of $2,231,826.30. Following the completion of the sale, the director owned 76,651 shares in the company, valued at approximately $1,941,569.83. This trade represents a 53.48% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 327,886 shares of company stock worth $8,628,256 in the last three months. 5.70% of the stock is owned by insiders.

Analyst Ratings Changes

Several brokerages have recently issued reports on PRVA. Weiss Ratings raised shares of Privia Health Group from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, July 2nd. Zacks Research raised shares of Privia Health Group from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 5th. Canaccord Genuity Group set a $32.00 price objective on shares of Privia Health Group in a report on Friday, August 7th. Barclays reduced their price objective on shares of Privia Health Group from $25.00 to $24.00 and set an “equal weight” rating on the stock in a research note on Tuesday, May 26th. Finally, Citigroup reaffirmed a “buy” rating on shares of Privia Health Group in a report on Thursday, July 23rd. Eleven equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $31.00.

Privia Health Group Company Profile

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.